Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pardanani

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Acta Haematologica|July 5, 2005
Systemic mastocytosis: bone marrow pathology, classification, and current therapiesA Pardanani
Leukemia|September 21, 2007
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trialsA Pardanani
Leukemia|January 31, 2012
Ruxolitinib for myelofibrosis therapy: current context, pros and consA Pardanani
Blood Reviews|July 12, 2011
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspectiveA Tefferi, A Pardanani
European Journal of Haematology|January 12, 2010
A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisionsA Pardanani, A Tefferi
Blood Cancer Journal|December 16, 2014
Definition and management of ruxolitinib treatment failure in myelofibrosisA Pardanani, A Tefferi
Best Practice & Research. Clinical Haematology|June 20, 2006
Pathogenesis, clinical features, and treatment advances in mastocytosisA Pardanani, C Akin, P Valent
Leukemia|May 21, 2010
Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cellsT Lasho, A Tefferi, A Pardanani
Leukemia|March 19, 2011
Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutationsT L Lasho, A Tefferi, C Finke, et al.
Journal of Molecular Biology|November 25, 1998
Mutational destabilization of the critical interface water cluster in Scapharca dimeric hemoglobin: structural basis for altered allosteric activityA Pardanani, A Gambacurta, F Ascoli, et al.
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Acta Haematologica|July 5, 2005
Systemic mastocytosis: bone marrow pathology, classification, and current therapiesA Pardanani
Leukemia|September 21, 2007
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trialsA Pardanani
Leukemia|January 31, 2012
Ruxolitinib for myelofibrosis therapy: current context, pros and consA Pardanani
Blood Reviews|July 12, 2011
JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspectiveA Tefferi, A Pardanani
European Journal of Haematology|January 12, 2010
A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisionsA Pardanani, A Tefferi
Blood Cancer Journal|December 16, 2014
Definition and management of ruxolitinib treatment failure in myelofibrosisA Pardanani, A Tefferi
Best Practice & Research. Clinical Haematology|June 20, 2006
Pathogenesis, clinical features, and treatment advances in mastocytosisA Pardanani, C Akin, P Valent
Leukemia|May 21, 2010
Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cellsT Lasho, A Tefferi, A Pardanani
Leukemia|March 19, 2011
Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutationsT L Lasho, A Tefferi, C Finke, et al.
Journal of Molecular Biology|November 25, 1998
Mutational destabilization of the critical interface water cluster in Scapharca dimeric hemoglobin: structural basis for altered allosteric activityA Pardanani, A Gambacurta, F Ascoli, et al.
Pageof 11